Physician profile
Mark B Stoopler
NPI 1295833937
$6,185.22
in general payments reported to CMS, 2019-2025
5 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $259 · 2022: $270 · 2024: $5,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,656.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $5,656.50 | 2024 | |
| Amgen INC. | $433.90 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $45.41 | 2022 | |
| Sirtex Medical INC | $25.00 | 2022 | |
| Jazz Pharmaceuticals INC. | $24.41 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Stoopler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.